Sanara MedTech (SMTI) Expected to Post Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Sanara MedTech to post earnings of ($0.0250) per share and revenue of $28.95 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $33.77 on Wednesday. The firm’s 50-day moving average is $24.50 and its 200-day moving average is $21.49. The company has a market cap of $309.29 million, a price-to-earnings ratio of -8.95 and a beta of 1.13. The company has a debt-to-equity ratio of 6.59, a quick ratio of 2.05 and a current ratio of 2.28. Sanara MedTech has a 52-week low of $16.05 and a 52-week high of $35.95.

Analyst Upgrades and Downgrades

SMTI has been the topic of a number of recent research reports. HC Wainwright downgraded Sanara MedTech from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $35.00 in a research report on Thursday, July 30th. Freedom Capital lowered Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Monday. Zacks Research upgraded Sanara MedTech from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. Lake Street Capital cut Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price for the company. in a research report on Thursday, July 30th. Finally, Wall Street Zen cut Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sanara MedTech currently has an average rating of “Reduce” and a consensus target price of $35.00.

Institutional Investors Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in shares of Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after purchasing an additional 1,171 shares during the last quarter. Wells Fargo & Company MN boosted its position in Sanara MedTech by 78.1% in the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after buying an additional 1,457 shares in the last quarter. Lazard Asset Management LLC grew its stake in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after buying an additional 3,155 shares during the last quarter. Deutsche Bank AG grew its stake in Sanara MedTech by 171.1% during the fourth quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock worth $93,000 after buying an additional 2,515 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after buying an additional 973 shares in the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.